Abstract
Abstract
Background
The widening supply–demand imbalance for kidneys necessitates finding ways to reduce rejection and improve transplant outcomes. Human leukocyte antigen (HLA) epitope compatibility between donor and recipient may minimize premature graft loss and prolong survival, but incorporating this strategy to deceased donor allocation criteria prioritizes transplant outcomes over wait times. An online public deliberation was held to identify acceptable trade-offs when implementing epitope compatibility to guide Canadian policymakers and health professionals in deciding how best to allocate kidneys fairly.
Methods
Invitations were mailed to 35,000 randomly-selected Canadian households, with over-sampling of rural/remote locations. Participants were selected for socio-demographic diversity and geographic representation. Five two-hour online sessions were held from November–December 2021. Participants received an information booklet and heard from expert speakers prior to deliberating on how to fairly implement epitope compatibility for transplant candidates and governance issues. Participants collectively generated and voted on recommendations. In the final session, kidney donation and allocation policymakers engaged with participants. Sessions were recorded and transcribed.
Results
Thirty-two individuals participated and generated nine recommendations. There was consensus on adding epitope compatibility to the existing deceased donor kidney allocation criteria. However, participants recommended including safeguards/flexibility around this (e.g., mitigating declining health). They called for a transition period to epitope compatibility, including an ongoing comprehensive public education program. Participants unanimously recommended regular monitoring and public sharing of epitope-based transplant outcomes.
Conclusions
Participants supported adding epitope compatibility to kidney allocation criteria, but advised safeguards and flexibility around implementation. These recommendations provide guidance to policymakers about incorporating epitope-based deceased donor allocation criteria.
Funder
Canadian Institutes of Health Research
Genome Canada
Genome British Columbia
Fonds de Recherche du Québec - Santé
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Kidney Foundation of Canada. Facing the Facts 2022: Highlights from the Annual Statistics on Organ Replacement in Canada. 2022. https://kidney.ca/KFOC/media/images/PDFs/Facing-the-Facts-2022.pdf. Accessed 3 Jun 2022.
2. Statistics Canada. Table 13–10–0394–01 Leading causes of death, total population, by age group. 2022. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401. Accessed 3 Jun 2022.
3. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Kidney transplantation compared with dialysis in clinically relevant outcomes: systematic review of kidney transplantation. Am J Transplant. 2011;11(10):2093–109.
4. Ferguson TW, Whitlock RH, Bamforth RJ, Beaudry A, Darcel J, Di Nella M, et al. Cost-utility of dialysis in Canada: hemodialysis, peritoneal dialysis, and nondialysis treatment of kidney failure. Kidney Med. 2021;3(1):20-30.e1.
5. Canadian Blood Services. Kidney paired donation. https://www.blood.ca/en/organs-tissues/living-organ-donation/kidney-paired-donation. Accessed April 26, 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献